The EUTOS long-term survival (ELTS) score is superior to the
Sokal score for predicting survival in chronic myeloid leukemia

J 2020

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

PFIRRMANN, M., R. E. CLARK, W. PREJZNER, M. LAUSEKER, M. BACCARANI et. al.

Basic information

Original name

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

Authors

PFIRRMANN, M. (276 Germany, guarantor), R. E. CLARK (826 United Kingdom of Great Britain and Northern Ireland), W. PREJZNER (616 Poland), M. LAUSEKER (276 Germany), M. BACCARANI (380 Italy), S. SAUSSELE (276 Germany), F. GUILHOT (250 France), S. HEIBL (40 Austria), R. HEHLMANN (276 Germany), E. FABER (203 Czech Republic), A. TURKINA (643 Russian Federation), G. OSSENKOPPELE (528 Netherlands), M. HOGLUND (752 Sweden), A. ZARITSKEY (643 Russian Federation), L. GRISKEVICIUS (440 Lithuania), U. OLSSON-STROMBERG (752 Sweden), H. EVERAUS (233 Estonia), P. KOSKENVESA (246 Finland), B. LABAR (191 Croatia), T. SACHA (616 Poland), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), F. CERVANTES (724 Spain), A. COLITA (642 Romania), I. ZUPAN (705 Slovenia), A. BOGDANOVIC (688 Serbia), F. CASTAGNETTI (380 Italy), J. GUILHOT (250 France), J. HASFORD (276 Germany), A. HOCHHAUS (276 Germany) and V. S. HOFFMANN (276 Germany)

Edition

Leukemia, London, Nature Publishing Group, 2020, 0887-6924

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 11.528

RIV identification code

RIV/00216224:14110/20:00116177

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1038/s41375-020-0931-9

UT WoS

000544139100003

Keywords in English

PROGNOSTIC DISCRIMINATION; IMATINIB TREATMENT; CML; VALIDATION; BOSUTINIB; DASATINIB; FRONTLINE; MODELS

Abstract

V originále

Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our aim was to compare the prognostic performance of the scores and to arrive at an evidence-based score recommendation. In 2949 patients not involved in any score development, higher hazard ratios and concordance indices in any comparison demonstrated the best discrimination of long-term survival with the ELTS score. In a second step, of 5154 patients analyzed to investigate risk group classification differences, 23% (n = 1197) were allocated to high-risk by the Sokal score. Of the 1197 Sokal high-risk patients, 56% were non-high-risk according to the ELTS score and had a significantly more favorable long-term survival prognosis than the 526 high-risk patients according to both scores. The Sokal score identified too many patients as high-risk and relatively few (40%) as low-risk (versus 60% with the ELTS score). Inappropriate risk classification jeopardizes optimal treatment selection. The ELTS score outperformed the Sokal score, the Euro, and the EUTOS score regarding risk group discrimination. The recent recommendation of the European LeukemiaNet for preferred use of the ELTS score was supported with significant statistical evidence.

Citovat

PFIRRMANN, M., R. E. CLARK, W. PREJZNER, M. LAUSEKER, M. BACCARANI, S. SAUSSELE, F. GUILHOT, S. HEIBL, R. HEHLMANN, E. FABER, A. TURKINA, G. OSSENKOPPELE, M. HOGLUND, A. ZARITSKEY, L. GRISKEVICIUS, U. OLSSON-STROMBERG, H. EVERAUS, P. KOSKENVESA, B. LABAR, T. SACHA, Daniela ŽÁČKOVÁ, F. CERVANTES, A. COLITA, I. ZUPAN, A. BOGDANOVIC, F. CASTAGNETTI, J. GUILHOT, J. HASFORD, A. HOCHHAUS and V. S. HOFFMANN. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. London: Nature Publishing Group, 2020, vol. 34, No 8, p. 2138-2149. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-020-0931-9.

@article{1673771,
   author = {Pfirrmann, M. and Clark, R. E. and Prejzner, W. and Lauseker, M. and Baccarani, M. and Saussele, S. and Guilhot, F. and Heibl, S. and Hehlmann, R. and Faber, E. and Turkina, A. and Ossenkoppele, G. and Hoglund, M. and Zaritskey, A. and Griskevicius, L. and OlssonandStromberg, U. and Everaus, H. and Koskenvesa, P. and Labar, B. and Sacha, T. and Žáčková, Daniela and Cervantes, F. and Colita, A. and Zupan, I. and Bogdanovic, A. and Castagnetti, F. and Guilhot, J. and Hasford, J. and Hochhaus, A. and Hoffmann, V. S.},
   article_location = {London},
   article_number = {8},
   doi = {http://dx.doi.org/10.1038/s41375-020-0931-9},
   keywords = {PROGNOSTIC DISCRIMINATION; IMATINIB TREATMENT; CML; VALIDATION; BOSUTINIB; DASATINIB; FRONTLINE; MODELS},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia},
   url = {https://www.nature.com/articles/s41375-020-0931-9.pdf},
   volume = {34},
   year = {2020}
}

TY  - JOUR
ID  - 1673771
AU  - Pfirrmann, M. - Clark, R. E. - Prejzner, W. - Lauseker, M. - Baccarani, M. - Saussele, S. - Guilhot, F. - Heibl, S. - Hehlmann, R. - Faber, E. - Turkina, A. - Ossenkoppele, G. - Hoglund, M. - Zaritskey, A. - Griskevicius, L. - Olsson-Stromberg, U. - Everaus, H. - Koskenvesa, P. - Labar, B. - Sacha, T. - Žáčková, Daniela - Cervantes, F. - Colita, A. - Zupan, I. - Bogdanovic, A. - Castagnetti, F. - Guilhot, J. - Hasford, J. - Hochhaus, A. - Hoffmann, V. S.
PY  - 2020
TI  - The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
JF  - Leukemia
VL  - 34
IS  - 8
SP  - 2138-2149
EP  - 2138-2149
PB  - Nature Publishing Group
SN  - 08876924
KW  - PROGNOSTIC DISCRIMINATION
KW  - IMATINIB TREATMENT
KW  - CML
KW  - VALIDATION
KW  - BOSUTINIB
KW  - DASATINIB
KW  - FRONTLINE
KW  - MODELS
UR  - https://www.nature.com/articles/s41375-020-0931-9.pdf
L2  - https://www.nature.com/articles/s41375-020-0931-9.pdf
N2  - Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our aim was to compare the prognostic performance of the scores and to arrive at an evidence-based score recommendation. In 2949 patients not involved in any score development, higher hazard ratios and concordance indices in any comparison demonstrated the best discrimination of long-term survival with the ELTS score. In a second step, of 5154 patients analyzed to investigate risk group classification differences, 23% (n = 1197) were allocated to high-risk by the Sokal score. Of the 1197 Sokal high-risk patients, 56% were non-high-risk according to the ELTS score and had a significantly more favorable long-term survival prognosis than the 526 high-risk patients according to both scores. The Sokal score identified too many patients as high-risk and relatively few (40%) as low-risk (versus 60% with the ELTS score). Inappropriate risk classification jeopardizes optimal treatment selection. The ELTS score outperformed the Sokal score, the Euro, and the EUTOS score regarding risk group discrimination. The recent recommendation of the European LeukemiaNet for preferred use of the ELTS score was supported with significant statistical evidence.
ER  -

PFIRRMANN, M., R. E. CLARK, W. PREJZNER, M. LAUSEKER, M. BACCARANI, S. SAUSSELE, F. GUILHOT, S. HEIBL, R. HEHLMANN, E. FABER, A. TURKINA, G. OSSENKOPPELE, M. HOGLUND, A. ZARITSKEY, L. GRISKEVICIUS, U. OLSSON-STROMBERG, H. EVERAUS, P. KOSKENVESA, B. LABAR, T. SACHA, Daniela ŽÁČKOVÁ, F. CERVANTES, A. COLITA, I. ZUPAN, A. BOGDANOVIC, F. CASTAGNETTI, J. GUILHOT, J. HASFORD, A. HOCHHAUS and V. S. HOFFMANN. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. \textit{Leukemia}. London: Nature Publishing Group, 2020, vol.~34, No~8, p.~2138-2149. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/s41375-020-0931-9.

Detailed Information on Publication Record